Vonjo
| Chemical Name | pacritinib |
| Dosage Form | Capsule (oral; 100 mg) |
| Drug Class | Kinase inhibitors |
| System | Blood |
| Company | CTI BioPharma |
| Approval Year | 2022 |
Indication
- For the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 × (10)^9/L.